Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II GLS-010 in relapsed or refractory classical Hodgkin lymphoma
ChiCTR1800018042Phase 2Recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of zimberelimab in classical Hodgkin lymphoma (cHL), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Objective response rate. Started Aug 2018; status: recruiting.
02
Drugs
zimberelimab
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on ChiCTR1800018042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800018042.